NCT06179485

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

Enrolling by Invitation
Not specifiedAges 18+Observational
Vanderbilt University Medical Center
~1,756 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:KetamineEtomidate

At a glance

Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PTSD Symptoms at 12 months
Measured over 12 months
Post-Traumatic Stress Disorder
Acute Respiratory Failure
6 sites across 5 states
Colorado2
Alabama1
Minnesota1
North Carolina1
Tennessee1

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Enrolled in RSI trial (NCT05277896)

Exclusion

Aphasic or non-verbal prior to tracheal intubation
Cannot follow commands prior to tracheal intubation
Non-English speaking
Deaf
  • PTSD Symptoms at 12 months12 months

    The investigators will measure PTSD symptoms at 3 and 12 months using the Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5). The PCL-5 is a widely used 5-10 minute patient survey validated to characterize severity of symptoms of PTSD. Patients rate 20 items corresponding to the DSM-5 criteria for PTSD on a 5-point Likert scale ranging from 0 (not bothersome) to 4 (extremely bothersome). Total scores range from 0 to 80, with higher scores indicating more severe symptoms of PTSD. Because a value for the PCL-5 score will not exist for patients who die prior to assessment, the main analysis will use a composite endpoint approach where patients whose PCL-5 could not be assessed because they died will be assigned a value of 81 (higher than the worst value on the PTSD symptom scale).